Physician profile
Farhad Jamali
NPI 1548248388
$19,134.27
in general payments reported to CMS, 2019-2025
66 companies · $2,665 in 2025
The $2,665 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,891 · 2020: $1,922 · 2021: $3,228 · 2022: $3,165 · 2023: $3,044 · 2024: $2,219 · 2025: $2,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,927.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,024.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,919.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,765.13 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,298.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,124.70 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,109.17 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $1,054.59 | 2019-2025 | |
| Horizon Therapeutics Plc | $837.24 | 2019-2023 | Krystexxa |
| Amgen INC. | $694.47 | 2019-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $646.46 | 2019-2025 | |
| Abbott Laboratories | $531.77 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $501.16 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $396.84 | 2019-2024 | Fanapt, Hetlioz |
| Exact Sciences Corporation | $396.02 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $373.25 | 2019-2023 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Jamali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.